RxDoctor Payments Data

Angelo Tellis, MD

Pain Medicine · New Bern, NCNPI 1922095520

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 583 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 57 manufacturers reported payments, led by Boston Scientific at 29.0% of the total.

$11,216in general payments, 2019–2025

Across 583 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AbbVie$1K
  • Medtronic$842
  • Nevro Corp.$744
  • Collegium Pharmaceutical, Inc.$560
  • Forte Bio-pharma LLC$379
  • plus $4K from 51 others

What the payments were for

  • Travel & lodging$1241%
  • Food & beverage$11,07199%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific166$3,248
AbbVie(2 entities)83$1,223
Medtronic(2 entities)45$842
Nevro Corp.26$744
Collegium Pharmaceutical, Inc.35$560
Forte Bio-pharma LLC10$379
Painteq LLC7$242
Scilex Pharmaceuticals Inc.19$230
Merz North America, Inc.5$205
Lundbeck LLC9$198
Virtus Pharmaceuticals LLC9$186
Bioventus LLC2$177
Vertos Medical, Inc.9$165
Curonix LLC2$155
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$148
Pfizer11$148
Biohaven Pharmaceutical Holding Company Ltd.8$137
Saluda Medical Americas, Inc.9$133
Redhill Biopharma Inc.6$120
Vertex5$117
Azurity Pharmaceuticals, Inc.6$115
Daiichi Sankyo Inc.9$108
Arbor Pharmaceuticals, Inc.8$106
Biodelivery Sciences International, Inc.8$104
Relievant Medsystems, Inc.4$103
SPR Therapeutics, Inc1$96
Sentynl Therapeutics, Inc.6$81
GRT US Holding, Inc.3$79
Biohaven Pharmaceuticals, Inc.6$78
Globus Medical3$76
Biotronik NRO, Inc.3$69
Stryker3$65
West Therapeutics Development, LLC4$61
Almatica Pharma LLC3$57
Fidia Pharma USA Inc.3$56
Upsher-smith Laboratories LLC4$55
Amgen(2 entities)3$49
Hikma Pharmaceuticals USA2$43
Kowa Pharmaceuticals America, Inc.3$42
Teva Pharmaceuticals USA, Inc.2$42
Zyla Life Sciences, Inc.3$35
Novo Nordisk2$34
Abbott2$32
Averitas Pharma Inc.1$31
Lilly USA, LLC2$31
Kaleo, Inc.2$23
Merz Pharmaceuticals, LLC1$21
Si-bone, Inc.1$20
Valinor Pharma, LLC1$19
Amneal Pharmaceuticals LLC1$19
Nalu Medical, Inc.1$18
Takeda Pharmaceuticals U.S.A., Inc.1$17
Idorsia Pharmaceuticals US Inc1$16
Protega Pharmaceutials Inc1$15
AstraZeneca1$15
Impel Pharmaceuticals Inc.1$15
Spinal Simplicity, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,216 in reported general payments places this provider in the 80th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$304,198
Medicare patients
411
Services billed
14,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate11$54,737
Xtampza ErOxycodone Myristate50$36,726
OxycontinOxycodone Hcl19$19,274
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen177$6,441
MovantikNaloxegol Oxalate16$5,955
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen158$4,725
Oxycodone Hcl224$4,642
Morphine Sulfate ErMorphine Sulfate63$2,487
Pregabalin64$1,488
Gabapentin145$1,390
Lidocaine14$1,256
Fentanyl11$1,023
Methadone Hcl28$812
Tizanidine Hcl39$457
Hydromorphone Hcl28$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Virtus Pharmaceuticals LLCLevorphanol Tartrate$186$54,73711 claims
Collegium Pharmaceutical, Inc.Xtampza Er$560$36,72650 claims
Redhill Biopharma Inc.Movantik$120$5,95516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →